Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors

Tissue Antigens. 2004 May;63(5):453-7. doi: 10.1111/j.0001-2815.2004.00203.x.

Abstract

"Cancer germline" genes such as those of the MAGE family are expressed in many tumors and in male germline cells but are silent in normal tissues. They encode shared tumor-specific antigens that have been used in therapeutic vaccination trials of cancer patients. We report the identification of a new MAGE-1-encoded peptide that is recognized by a cytolytic T-lymphocyte (CTL) clone on human leukocyte antigen (HLA)-B*5701. The sequence of the peptide, corresponding to position 102-112 of the MAGE-1 protein sequence, is ITKKVADLVGF. When tumor cells expressing MAGE-1 were transfected with HLA-B*5701, they were lyzed by the CTL clone, indicating that the peptide is processed in tumor cells and can, therefore, be used as a target for anti-tumoral vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / immunology*
  • Base Sequence
  • Cell Line, Tumor
  • Cell Transformation, Viral
  • HLA-B Antigens / immunology*
  • Herpesvirus 4, Human
  • Humans
  • Melanoma-Specific Antigens
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / immunology*
  • Peptides / immunology*
  • T-Lymphocytes, Cytotoxic / immunology*

Substances

  • Antigens, Neoplasm
  • HLA-B Antigens
  • MAGEA1 protein, human
  • Melanoma-Specific Antigens
  • Neoplasm Proteins
  • Peptides